Zhejiang Hisoar Pharmaceutical Co Ltd (SHE:002099) — Market Cap & Net Worth

$1.27 Billion USD  · CN¥8.68 Billion CNY  · Rank #7913

Market Cap & Net Worth: Zhejiang Hisoar Pharmaceutical Co Ltd (002099)

Zhejiang Hisoar Pharmaceutical Co Ltd (SHE:002099) has a market capitalization of $1.27 Billion (CN¥8.68 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #7913 globally and #1802 in its home market, demonstrating a 2.88% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Hisoar Pharmaceutical Co Ltd's stock price CN¥5.36 by its total outstanding shares 1618715253 (1.62 Billion). Also see Zhejiang Hisoar Pharmaceutical Co Ltd asset portfolio for a full breakdown of the balance sheet.

Zhejiang Hisoar Pharmaceutical Co Ltd Market Cap History: 2015 to 2026

Zhejiang Hisoar Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.48 Billion to $1.27 Billion (-4.82% CAGR). Also see 002099 cash flow conversion for how efficiently the company converts equity into cash flow.

Zhejiang Hisoar Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Zhejiang Hisoar Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 002099 stock price for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

0.63x

Zhejiang Hisoar Pharmaceutical Co Ltd's market cap is 0.63 times its annual revenue

Industry average: 0.57x Higher than industry average

Latest Price to Earnings (P/E) Ratio

N/A

P/E ratio not applicable due to negative or zero earnings

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2015 $2.48 Billion $2.46 Billion $516.59 Million 1.01x 4.80x
2016 $1.78 Billion $2.43 Billion $225.02 Million 0.73x 7.92x
2017 $1.22 Billion $2.31 Billion $342.22 Million 0.53x 3.57x
2018 $972.65 Million $2.72 Billion $605.00 Million 0.36x 1.61x
2019 $1.58 Billion $2.94 Billion $770.78 Million 0.54x 2.05x
2020 $1.97 Billion $2.47 Billion $319.72 Million 0.80x 6.15x
2021 $1.91 Billion $2.48 Billion $95.23 Million 0.77x 20.07x
2022 $1.65 Billion $2.70 Billion $88.01 Million 0.61x 18.75x
2023 $1.70 Billion $2.17 Billion -$420.06 Million 0.78x N/A
2024 $1.22 Billion $1.94 Billion -$330.27 Million 0.63x N/A

Competitor Companies of 002099 by Market Capitalization

Companies near Zhejiang Hisoar Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review Zhejiang Hisoar Pharmaceutical Co Ltd (002099) tangible net worth to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Zhejiang Hisoar Pharmaceutical Co Ltd by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#518 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#613 GALDERMA GROUP AG NYSE:GALDY $44.92 Billion $38.53
#635 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €16.90
#670 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $40.99 Billion CN¥43.91

Zhejiang Hisoar Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, Zhejiang Hisoar Pharmaceutical Co Ltd's market cap moved from $2.48 Billion to $ 1.27 Billion, with a yearly change of -4.82%.

Year Market Cap Change (%)
2026 CN¥1.27 Billion -14.10%
2025 CN¥1.48 Billion +20.93%
2024 CN¥1.22 Billion -28.23%
2023 CN¥1.70 Billion +3.19%
2022 CN¥1.65 Billion -13.66%
2021 CN¥1.91 Billion -2.81%
2020 CN¥1.97 Billion +24.53%
2019 CN¥1.58 Billion +62.39%
2018 CN¥972.65 Million -20.28%
2017 CN¥1.22 Billion -31.52%
2016 CN¥1.78 Billion -28.14%
2015 CN¥2.48 Billion --

End of Day Market Cap According to Different Sources

On Sep 19th, 2026 the market cap of Zhejiang Hisoar Pharmaceutical Co Ltd was reported to be:

Source Market Cap
Yahoo Finance $1.27 Billion USD
MoneyControl $1.27 Billion USD
MarketWatch $1.27 Billion USD
marketcap.company $1.27 Billion USD
Reuters $1.27 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Zhejiang Hisoar Pharmaceutical Co Ltd

SHE:002099 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.27 Billion
CN¥8.68 Billion CNY
Market Cap Rank
#7913 Global
#1802 in China
Share Price
CN¥5.36
Change (1 day)
-0.74%
52-Week Range
CN¥4.98 - CN¥8.83
All Time High
CN¥11.31
About

Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes in China and internationally. The company offers antibiotics, cardiovascular, hypoglycemic, fine chemicals, formulations, intermediates, and other products. It also provides dyestuff, and intermediates of dyestuff and pigment; and manufactures environmental protection related equipment, medical… Read more